{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/obsessive-compulsive-disorder/supporting-evidence/combination-treatments-in-adults/","result":{"pageContext":{"chapter":{"id":"d63bb159-7b2d-54b3-a251-0fb81b09618f","slug":"combination-treatments-in-adults","fullItemName":"Combination treatments in adults","depth":2,"htmlHeader":"<!-- begin field b287db4c-5f1d-41ae-9267-c5d032950559 --><h2>Evidence on combination treatments in adults</h2><!-- end field b287db4c-5f1d-41ae-9267-c5d032950559 -->","summary":null,"htmlStringContent":"<!-- begin item f8d21f16-7ea1-41ee-8f59-8011c28832f0 --><!-- begin field c74defc7-6409-4410-84e7-bf8366ebb44e --><p><strong>There is limited evidence from a systematic review commissioned by the National Institute for Health and Clinical Excellence (NICE) (five randomized controlled trials [RCTs], n = 404) and one subsequent RCT (n = 102) that combined treatment with cognitive-behavioural therapy (CBT) and a selective serotonin reuptake inhibitor (SSRI) or clomipramine is superior in efficacy to either treatment alone. Evidence from one follow-up study (n = 102) suggests there is no significant difference in long-term outcome between a combination of CBT and fluvoxamine, and CBT alone.</strong></p><ul><li>The systematic review (including studies on adults, providing efficacy data on 404 participants and tolerability data on 414 participants) found that combined exposure and response prevention (ERP) and an SSRI or clomipramine was superior to either ERP alone or an SSRI or clomipramine alone in treating adults with obsessive-compulsive disorder (OCD); the authors did not perform a meta-analysis on all the data, presumably owing to heterogeneity [<a class=\"bibliography-reference internal-reference\" href=\"/topics/obsessive-compulsive-disorder/references/\">National Collaborating Centre for Mental Health, 2006</a>]:<ul><li>The evidence was inconclusive with regard to any differences in tolerability.</li><li>The level of severity of functional impairment of the participants is not clear.</li><li>Studies lasted between 8 and 24 weeks.</li></ul></li><li>A subsequent RCT compared ERP with a control CBT (stress management training) in 108 adults with OCD who were already taking, and had responded to treatment with, an SSRI or clomipramine [<a class=\"bibliography-reference internal-reference\" href=\"/topics/obsessive-compulsive-disorder/references/\">Simpson et al, 2008</a>]:<ul><li>There was a statistically significant difference in the reduction of the mean Y-BOCS score after 8 weeks in favour of ERP, reported as an effect size (the difference between means divided by pooled standard deviation) of 1.31 (95% CI 0.86 to 1.75).</li><li>There was also a statistically significant difference in treatment response (25% or more reduction in Y-BOCS score) in favour of ERP (74% versus 22%; p < 0.001).<!--_c2a0_0.00129_.  --></li><li>Although the authors do not state that results were analysed by intention-to-treat, there were very few drop-outs in each group (4% in the ERP group and 2% in the stress management training group).</li></ul></li><li>One follow-up study (n = 102), which assessed subjects 5 years after treatment, found no statistically significant difference in obsessive-compulsive symptoms (as measured by a variety of scores including Y-BOCS) between a combination of CBT and fluvoxamine, and CBT alone (p = 0.33) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/obsessive-compulsive-disorder/references/\">van Oppen et al, 2005</a>]. However:<ul><li>Improvements following treatment were maintained after 5 years in both groups.</li><li>Participants who had received CBT and fluvoxamine were more likely than those who had received CBT alone to be on an antidepressant after 5 years.</li></ul></li></ul><!-- end field c74defc7-6409-4410-84e7-bf8366ebb44e --><!-- end item f8d21f16-7ea1-41ee-8f59-8011c28832f0 -->","topic":{"id":"1f37cc0e-7573-58d0-a414-18973c123eae","topicId":"394f419d-3ab3-4fd3-85c7-7ae0c286d323","topicName":"Obsessive-compulsive disorder","slug":"obsessive-compulsive-disorder","lastRevised":"Last revised in June 2018","chapters":[{"id":"6854ef67-5e05-528c-afeb-b7680f464892","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"0151ee13-83cc-5d06-9ce4-f03bc14a2d91","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"a6ac8f0f-9ef4-5778-82e7-0ee23afbaaf8","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"f571042f-c058-5f39-a22d-6901a3f9f4d0","slug":"changes","fullItemName":"Changes"},{"id":"31a9215e-18d0-5bd1-9341-846c7185dd16","slug":"update","fullItemName":"Update"}]},{"id":"39a21515-e7bc-515d-80d4-420f429a801f","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"9c01874c-054d-55f7-bc72-c5dc572bb4ce","slug":"goals","fullItemName":"Goals"},{"id":"bb1af94d-3d5a-5862-9e75-51cfd39e9e31","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"31dd33b1-cd86-57bc-84c1-206363cae677","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"8aa2028a-8646-59f5-ac0b-c585d5f9474a","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"96f32bee-6f1f-5862-8163-8f9adf02e81e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"0c41f244-6591-5043-825b-f48000a19060","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"69296d43-e92e-51ad-803f-9b00dd4ef3eb","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"23304d59-7975-500a-9672-1d71c224d42b","slug":"definition","fullItemName":"Definition"},{"id":"75facf2a-3aa9-52ec-a213-c09d7c49305a","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"ef703cf4-f71d-53e8-ac6e-55fd3949af89","slug":"prevalence","fullItemName":"Prevalence"},{"id":"16615ebe-7c11-54ea-8c8f-11b27bd84df0","slug":"prognosis","fullItemName":"Prognosis"},{"id":"9c3a46c7-846c-5e14-9297-e80dfc82ffa5","slug":"complications","fullItemName":"Complications"}]},{"id":"9063127c-d315-5f06-81a4-0854a79730a5","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"8e2a1f2f-09ef-5f73-a3ec-2aac2b0a90b7","slug":"diagnosis","fullItemName":"Diagnosis"}]},{"id":"d07d5382-3d58-534c-80b0-ebb514c9d790","fullItemName":"Management","slug":"management","subChapters":[{"id":"adfa1e25-924b-5e4d-b909-bbd62bfa3981","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"1a83f73e-9ca7-5f30-9cda-aaa563048a36","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"0b63ad08-27a9-5af8-8fb8-6940aa3d3dc3","slug":"ssris","fullItemName":"SSRIs"},{"id":"32401b30-535f-57bf-8154-4e5efa0884e3","slug":"clomipramine","fullItemName":"Clomipramine"}]},{"id":"34094942-974d-50ae-b83e-52a2243c1e47","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[{"id":"06ebd4e9-a6ff-5645-8bf1-4a06d03e073b","slug":"psychological-treatments-in-adults","fullItemName":"Psychological treatments in adults"},{"id":"73a36a4c-8f66-5d63-a4ad-c1667bd42f3b","slug":"ssris-in-adults","fullItemName":"SSRIs in adults"},{"id":"f077f54e-c77f-533b-84b3-6f81c9eb4f89","slug":"pharmacological-versus-psychological-treatments-in-adults","fullItemName":"Pharmacological versus psychological treatments in adults"},{"id":"d63bb159-7b2d-54b3-a251-0fb81b09618f","slug":"combination-treatments-in-adults","fullItemName":"Combination treatments in adults"}]},{"id":"ed477751-4d36-5e3b-bfcb-60739e1daea7","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"6e26607d-6208-5c71-a5ee-ba2bd8567311","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"700ff2f4-6d6b-5235-8301-91ad6701f206","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"20682403-8c70-5f97-86c4-1f8234b42261","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"9242ca74-0efb-54f8-9cb4-267acc46dc6c","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"8a264e61-1997-5859-8b1d-e1d859ffa219","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"c91ccb0b-b8e6-5c2a-ab14-79b9eff3e63a","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"34094942-974d-50ae-b83e-52a2243c1e47","slug":"supporting-evidence","fullItemName":"Supporting evidence"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}